Maternal serum alpha fetoprotein levels are used for screening all of the following congenital defects, EXCEPT:
**Question:** Maternal serum alpha fetoprotein levels are used for screening all of the following congenital defects, EXCEPT:
A. Anencephaly
B. Polyhydramnios
C. Ascites
D. Cystic hygroma
**Core Concept:**
Maternal serum alpha fetoprotein (AFP) levels are used as a screening test for certain congenital defects during pregnancy. Alpha fetoprotein is a protein produced by the fetus during pregnancy and can be measured in the mother's blood. This test is used to screen for certain abnormalities in the fetus that affect the central nervous system (CNS), such as neural tube defects (NTDs).
**Why the Correct Answer is Right:**
In this case, the correct answer is "Ascites" because ascites is a condition characterized by the accumulation of fluid in the abdominal cavity due to liver disease or heart failure. It is not a congenital defect affecting the fetus. The other options, Anencephaly, Polyhydramnios, and Cystic Hygroma, are all examples of congenital defects involving the fetus's central nervous system (CNS) and are screened by measuring AFP levels in the mother's blood.
**Why Each Wrong Option is Incorrect:**
A. Anencephaly: This is a severe neural tube defect where the brain and skull are underdeveloped, leading to anencephaly. AFP screening is used to detect this type of defect.
B. Polyhydramnios: This is excessive accumulation of amniotic fluid, which can be related to fetal lung maturity issues or polycystic kidney disease. AFP screening is not relevant to this condition.
C. Cystic Hygroma: This is a swelling in the neck caused by the accumulation of fluid in the lymphatic system. AFP screening is used for neural tube defects, not lymphatic disorders.
**Clinical Pearl:**
Maternal serum AFP screening is a valuable tool for detecting certain congenital defects, particularly neural tube defects (NTDs) such as anencephaly, spina bifida, and encephalocele. By measuring AFP levels, healthcare professionals can identify increased risk for these defects and perform further diagnostic tests to confirm the diagnosis. This allows for early intervention, improving pregnancy outcomes and reducing the risk to the fetus.